Alexandra Cantley
Partner @ Polaris Partners
New York, United States
Alexandra Cantley is a Series A investor at Polaris Partners in New York focused on Biotechnology and Health Care. Alexandra joined Polaris in 2019 and serves as a partner in the New York office. She is primarily focused on early stage biotech and healthcare investments. She currently serves on the Board of Directors of Podimetrics and as a Board Observer to Auron Therapeutics, Engine Bio, and SunBird Bio. Prior to joining Polaris, Alexandra was part of theinitial research team at Inzen Therapeutics, where she helped develop their platform technologies. She moved to Inzen from Vertex Pharmaceuticals, where she held a research fellowship. Alexandra received a PhD in Chemical Biology from Harvard University, where she studied natural product discovery. Alexandra performed her undergraduate studies at New York University.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Alexandra Cantley invests in
Stages Alexandra Cantley invests in
Countries Alexandra Cantley invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (50%)
- Health Care 3 (38%)
- Medical 2 (25%)
- Therapeutics 2 (25%)
- Biopharma 1 (13%)
Stage
- Series A 3 (38%)
- Series B 3 (38%)
- Funding Round 1 (13%)
- Venture - Series Unknown 1 (13%)
Country
- United States 3 (38%)
- Singapore 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $50M / Jan 27, 2026 | ||
| EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. | $107M / Series B / Jan 08, 2026 | ||
| Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $27.3M / Series B / Feb 04, 2025 | ||
| TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $84M / Series B / Nov 13, 2024 | ||
| Sunbird Bio is a diagnostics platform developer that aims to give molecular diagnostics with faster outcomes. Sunbird Bio was founded by Huilin Shao. | $14M / Venture - Series Unknown / Oct 16, 2024 | ||
| EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. | $73.1M / Series A / Mar 22, 2023 | ||
| Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $48M / Series A / Jul 20, 2022 | ||
| TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $26M / Series A / Mar 08, 2022 |
Co-Investors
About Polaris Partners
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
Polaris Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Isaac Ciechanover
Partner
|
|||
Marissa Bertorelli
Principal
|
|||
Sharif Vakili
Associate
|
|||
Alan Crane
Partner and Entrepreneur
|
|||
|
Alexandra Cantley
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alexandra Cantley invest in?
Alexandra Cantley invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alexandra Cantley?
Public channels for Alexandra Cantley include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alexandra Cantley last invest?
The most recent investment recorded for Alexandra Cantley closed in Jan 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
